Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled study of SLN360 in adults with elevated lipoprotein(a)
NL-OMON55119Phase 1Completed
- Sponsor
- Silence Therapeutics
- Start
- Feb 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing SLN360 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single or multiple doses of SLN360. Started Feb 2022; status: completed.
02
Drugs
zerlasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON55119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55119.